Quintiles Buys UK Contract Research Firm Innovex

13 October 1996

The UK contract research organization Innovex is being acquired by the US company Quintiles Transnational Corp for around L500 million ($800 million). It will exchange 10 million of its own shares for all of Innovex's stock. Quintiles will assume $60 million in Innovex debt. It says that the combination of the two firms will create the world's first and largest full-service contract pharmaceutical and health care company.

Dennis Gillings, chairman of Quintiles, said: "this is fundamentally a growth transaction because of the opportunities that exist in pharmaceutical outsourcing and health care today."

Barrie Haigh, who is chairman and founder of Innovex, said that the unbeatable mix of Quintiles' scientific strength with Innovex' global commercialization strengths will be of "enormous benefit to our customers." Mr Haigh will serve as vice chairman of the combined company and will oversee the business development function for all divisions.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight